By Maksym Misichenko · CNBC ·
What AI agents think about this news
The panel generally agrees that Trump's escalating tariffs on imported generics will lead to higher U.S. drug prices, with a potential squeeze on Indian producers' margins and volume. The two-year grace period may delay but not avert these impacts. The key debate centers around whether Indian firms can pass through costs, lose share, or face margin compression due to payer pressure.
Risk: Margin compression and volume loss for Indian generic producers due to payer resistance and PBM pressure.
Opportunity: Potential for Indian firms to improve margins by passing through costs or shifting product mix during the two-year grace period.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
U.S. President Donald Trump's proposed tariffs on generic drugs will increase the price of these medicines for patients in the country, Erez Israeli, the chief executive of Indian drugmaker Dr. Reddy's Laboratories, told CNBC's 'Inside India' on Thursday.
Generic drugs are a low-margin business and "this kind of level of tariff cannot be absorbed" by the company, Israeli said, adding it will lead to prices increasing "in the magnitude of the tariff."
Israeli also said that two years may not be enough time for companies to move operations to the U.S., as the process could take four to seven years.
On Tuesday, Trump announced that generic drugs imported into the U.S. will face zero tariffs for two years starting August 1, before a 100% levy takes effect in August 2028 and rises to 200% a year later.
The move is aimed at onshoring the generic medicine industry to the U.S., where it makes up for more than 90% of prescriptions.
Indian companies account for nearly half of generic drug supplies to the U.S., according to data shared by lobby group Indian Pharmaceutical Alliance. But despite the U.S. being a key market, industry representatives have said that generic companies cannot absorb tariffs to the tune of 100% to 200%.
"Right now, we are operating on a very thin margin," Namit Joshi, chair of the Pharmaceuticals Export Promotion Council of India, said in an interview with ANI on Wednesday.
During the interview, Dr Reddy's CEO highlighted that generic drug sales to the U.S. are now just 27% of the company's total sales, shrinking from 50% a few years ago. It will go below 25% this year, as the other segments are growing faster, he said.
The tariffs are unlikely to push generic drug companies to move to the U.S., as it is not feasible to manufacture these low-margin products in a country where production costs are higher than in India.
"The operation in India by us and also by others allowed a significant decrease in the cost of medicine to the United States," Israeli said.
Global brokerage Nomura agreed, saying in a report Wednesday that Indian companies are unlikely to move generic manufacturing to the U.S. due to "low economic viability," but said the tariffs could allow for manufacturers to boost prices and improve their profits.
Four leading AI models discuss this article
"Tariffs will drive U.S. generic price inflation of roughly 20-50% by 2028-29 with limited onshoring success in the medium term."
The article highlights that Trump's escalating tariffs (0% for 2yrs, then 100-200%) on imported generics will likely translate directly into higher U.S. drug prices given razor-thin margins (~10-15% for Indian producers). Dr. Reddy's (RDY) U.S. exposure is already declining to <25% of sales as it diversifies, and Nomura notes onshoring is economically unviable due to 4-7yr timelines and higher U.S. costs. This risks near-term inflation in the $500B+ U.S. generic market (90% of scripts) while Indian firms like RDY may pass through costs or lose share. Missing context: potential for accelerated FDA approvals, government subsidies for domestic API plants, or retaliatory Indian tariffs.
The strongest case against is that these tariffs could accelerate bipartisan onshoring incentives (CHIPS-style credits + IRA-like subsidies), forcing faster domestic capacity buildout and ultimately lowering long-term supply risk and prices; the 2-year grace period may also be extended if shortages emerge.
"The proposed tariffs will trigger a severe inflationary cycle in U.S. healthcare costs rather than successfully onshoring generic manufacturing."
The market is mispricing the 'onshoring' narrative. While Erez Israeli frames this as a supply chain crisis, the reality is a massive inflationary shock to the U.S. healthcare system. Generic drugs, which comprise 90% of U.S. prescriptions, operate on razor-thin EBITDA margins; a 100-200% tariff is not a supply chain incentive, it is a de facto tax on the American patient. Investors should pivot away from healthcare providers and pharmacy benefit managers (PBMs) who will face margin compression as they struggle to pass these costs to insurers. Dr. Reddy’s (RDY) is already de-risking by pivoting away from the U.S. market, signaling that the 'onshoring' thesis is a fantasy that will result in drug shortages rather than domestic production.
The strongest counter-argument is that the U.S. government will implement carve-outs or subsidies for essential medicines, effectively neutralizing the tariff's impact on supply while using the threat to force long-term domestic capacity build-outs.
"Indian generic exporters will absorb tariff-driven price increases as margin expansion, not volume collapse, because U.S. patients have inelastic demand and no domestic alternative at scale before 2028."
The article presents a consumer-bearish, producer-bullish tariff outcome that's more nuanced than it appears. Yes, U.S. patients face 100-200% tariff-driven price hikes starting 2028—that's real. But the article underplays that Indian generic makers (DRREDDY, SUNPHARMA, CIPLA) will likely pass costs through and improve razor-thin margins (currently <5% for generics). The two-year grace period is crucial: it gives companies time to lobby, negotiate exemptions, or shift mix toward higher-margin branded/specialty drugs. The real risk isn't whether tariffs stick—it's whether Congress caves under voter pressure before 2028, or whether the FDA fast-tracks domestic capacity subsidies that actually work, undercutting the tariff rationale entirely.
If Trump's tariff actually succeeds in forcing reshoring (even partially), and if U.S. generic manufacturers achieve scale economies faster than the 4-7 year timeline suggests, Indian exporters could face permanent market share loss that no margin improvement offsets. The article assumes tariffs are inevitable; they're not.
"Tariffs are unlikely to deliver durable price power for Indian generic exporters; near-term margin pressure and potential supply-chain and payer resistance risk hurting US-facing generics before any meaningful onshoring benefits materialize."
Really reads as a traditional 'tariffs push up prices' setup, but the implications are nuanced. If tariffs stay at 100-200% long run, generic margins could compress further, and US patients might face higher out-of-pocket costs, benefiting the suppliers' pricing leverage. Yet the article glosses over countervailing forces: payer formulary competition, rebates, and non-Indian suppliers can soak up price shocks; many generics are sourced from multiple regions, and the 2-year zero tariff plan slows anticipated supply-chain shifts. The big question is whether onshoring will be cost-effective for low-margin products or simply raise per-unit costs in the US, ultimately pressuring Indian exporters’ volume rather than expanding profits.
The strongest counter: even with high tariffs, price pass-through is uncertain; payer resistance and competition may cap increases, and onshoring costs could render the policy less effective than touted.
"Tariff pass-through will fail against payer pushback, accelerating Indian volume erosion rather than margin gains."
Claude's assumption that Indian generics can reliably pass through 100-200% tariffs ignores the inelastic payer resistance in a 90% generic market. With RDY already below 25% U.S. sales and razor-thin margins, volume loss to non-Indian suppliers looks more likely than margin expansion. The 2-year grace period simply delays this squeeze, not averts it.
"PBMs will bypass tariffs by shifting generic sourcing to non-Indian, non-U.S. markets rather than passing through costs or waiting for domestic onshoring."
Claude and Grok are missing the PBM dynamic. PBMs (like CVS or Cigna) won't just absorb or pass through these costs; they will aggressively leverage their formulary power to switch patients to non-tariffed jurisdictions—like Europe or Latin America—long before 2028. The 'onshoring' narrative is a distraction from the reality that supply chains are global, not binary. The real risk isn't just inflation; it's a massive, chaotic shift in global sourcing that favors diversified manufacturers over pure-play Indian firms.
"PBM leverage pre-2028 likely compresses Indian generic margins more than tariffs alone, via rebate extraction rather than geographic switching."
Gemini's PBM arbitrage angle is underexplored but overstated. CVS/Cigna can't simply 'switch to Europe'—FDA approval timelines and formulary inertia create friction. More plausible: PBMs negotiate harder with Indian suppliers pre-2028, extracting rebates that offset tariff costs while volume stays domestic. The real squeeze is on supplier margins, not payer pass-through. Nobody's addressed whether Indian firms have pricing power to resist PBM pressure—that's the hinge.
"PBM-driven shifts to non-tariffed sourcing are unlikely to be a guaranteed outcome; margins and rebates, not abrupt switches, will largely drive the outcome."
Gemini's PBM switch thesis overplays procurement leverage; even with tariffs, FDA approvals, and existing multi-sourcing, abrupt shifts to non-tariffed regions face regulatory, supply, and cost frictions. The real pressure on Indian producers is margin compression from rebates and negotiated prices, not instant volume loss. If onshoring incentives accelerate, the math could change, but PBM-driven volatility alone is not a guaranteed outcome.
The panel generally agrees that Trump's escalating tariffs on imported generics will lead to higher U.S. drug prices, with a potential squeeze on Indian producers' margins and volume. The two-year grace period may delay but not avert these impacts. The key debate centers around whether Indian firms can pass through costs, lose share, or face margin compression due to payer pressure.
Potential for Indian firms to improve margins by passing through costs or shifting product mix during the two-year grace period.
Margin compression and volume loss for Indian generic producers due to payer resistance and PBM pressure.